Biofrontera (NASDAQ:BFRI) Receives New Coverage from Analysts at Roth Capital

Roth Capital assumed coverage on shares of Biofrontera (NASDAQ:BFRI) in a report issued on Wednesday morning, Price Targets.com reports. The firm issued a buy rating and a $20.00 price target on the stock.

NASDAQ:BFRI opened at $5.22 on Wednesday. Biofrontera has a 1-year low of $2.25 and a 1-year high of $7.36.

About Biofrontera

Biofrontera Inc is a biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on the fields of photodynamic therapy and topical antibiotics. The Company’s licensed products focus on the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.

Featured Story: When can a hold rating present a buying opportunity?

Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.